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a  b  s  t  r  a  c  t
Disease-speciﬁc  mortality  is  the  ﬁnal  outcome  of  a  lung  cancer  screening  trial,  therefore  cause  of  death
veriﬁcation  is  crucial.  The  use  of  death  certiﬁcates  for this  purpose  is  debated  because  of  bias,  inaccurate
completion  and  incorrect  ante  mortem  diagnoses.  A cause  of  death  evaluation  process  was  designed  to
ensure  a uniform  and  unbiased  determination  of  the  graduation  of certainty  that lung  cancer  was  the
underlying  cause  of  death.  An independent  clinical  expert  committee  will review  the  medical  ﬁles  of  all
deceased  participants  once  diagnosed  with  lung  cancer  and  will make  use  of  a ﬂow  chart  and  predeter-
mined  criteria.  A  pilot  study  of  ﬁfty  cases  was  conducted  to  determine  the  performance  of this  process  andeath certiﬁcates
eath review
ung cancer
creening
to  compare  the  outcome  with  the  ofﬁcial  death  certiﬁcates.  The  independent  review  has  shown  an  agree-
ment of  90%  (kappa  0.65),  which  demonstrates  a uniform  classiﬁcation.  The  sensitivity  and  speciﬁcity  of
the death  certiﬁcates  for  lung  cancer  speciﬁc  mortality  were  95.2  and  62.5%.  This  demonstrates  a  limited
distinctive  character  of  the  death  certiﬁcation  process  in lung  cancer  patients.  Our  results  imply  that
the ﬁnal  outcome  of a lung  cancer  screening  trial  cannot  reliably  be established  without  predetermined
criteria  and  an  independent  review  of  blinded  cases.
© 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license. . Introduction
Lung cancer is the ﬁrst cause of cancer-related death in males
nd the second in females globally, accounting for 1.4 million
eaths per year [1].  Despite treatment advances, survival has not
mproved substantially over the past 30 years, mainly because
he majority of the patients have distant metastasis at the time
f diagnosis [2].  The early detection of lung cancer by screening
symptomatic smokers with low dose computer tomography (CT)
canning is a promising strategy to reduce lung cancer mortality,
 Trial registration number: ISRCTN63545820.
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edical Centre Rotterdam, P.O. Box 2040, room Ae108, 3000 CA Rotterdam, The
etherlands. Tel.: +31 107044095; fax: +31 107038474.
E-mail address: n.horeweg@erasmusmc.nl (N. Horeweg).
1 Current address: Lievensberg Hospital, Boerhaaveplein 1, 4600 AC Bergen op
oom, The Netherlands.
169-5002 ©  2012 Elsevier Ireland Ltd. 
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Open access under the Elsevier OA license. since the results of the National Lung Screening Trial (NLST) were
published [3,4].
Disease-speciﬁc mortality is the outcome of lung cancer screen-
ing; therefore, cause of death (CoD) veriﬁcation is crucial. The use
of death certiﬁcates for this purpose is debated for several reasons.
Firstly, two  forms of bias especially affect death certiﬁcation in
screening trials. Sticky-diagnosis bias; because lung cancer is more
likely to be diagnosed in the screen arm, deaths are more likely
to be attributed to lung cancer compared to the usual care arm
[5]. Slippery-linkage bias; deaths as a result of interventions for
lung cancer may  be difﬁcult to trace back to screening and could
easily be certiﬁed as death due to other causes [5].  Secondly, the
merit of death certiﬁcates depends on the accuracy of the certify-
ing clinician and nosologist and the establishment of a correct ante
mortem diagnosis [6,7]. Common reasons for misclassiﬁcation are
coinciding malignancies, considerable comorbidity and death after
a surgical procedure [8,9]. Finally, the sensitivity and speciﬁcity of
the death certiﬁcate has been reported to range from 84.5 to 99.7%
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Table 1
Classiﬁcation of the cause of death.
Cause of death Deﬁnition
Deﬁnitely lung cancer
death
Death certainly as a direct result of (second
primary) lung cancer, a paraneoplastic
syndrome or a diagnostic or therapeutic
intervention, including euthanasia and
palliative sedation. No clear other cause of
death is present.
Probable lung cancer
death
Participants with (second primary) lung cancer
with evidence of locoregional or distant
disease progression or a paraneoplastic
syndrome. It is uncertain whether this is the
ﬁnal direct cause of death. No clear other cause
of  death is present.
Possible lung cancer
death
Participants with (second primary) lung cancer
with evidence of locoregional or distant
disease progression or a paraneoplastic
syndrome and one or more coinciding
malignancies. It is not possible to determine
which malignancy was  the primary cause of
death.
Unlikely lung cancer
death
Participants with (second primary) lung
cancer, but without evidence of locoregional or
distant disease progression, a paraneoplastic
syndrome or death as a result of an
intervention for lung cancer. No clear other
cause of death is present.
Deﬁnitely no lung
cancer death
The cause of death is deﬁnitely not a direct or
indirect result from (second primary) lung
cancer, a paranoplastic syndrome or an
intervention for lung cancer. Another cause of
death is present.
Intercurrent death
with lung cancer as
contributing factor
Only use this option when the cause of death
cannot be classiﬁed as listed above. The cause
of death is deﬁnitely not a direct result from
(second primary) lung cancer. Another cause ofN. Horeweg et al. / Lun
nd 91.3 to 99.7%; causing an error that tends to reduce the effect
f screening [9–12].
To overcome these problems clinical expert committees (CEC),
eviewing the medical ﬁles of the deceased participants to deter-
ine the cause of death, are frequently employed in cancer
creening trials [9–14]. The additional value of a CEC depends on
he use of predetermined criteria and a thorough and independent
valuation of all cases with lung cancer blind towards each arm, to
revent an unbalanced outcome between the study arms.
We hypothesized that a clinical expert committee cannot reli-
bly establish the outcome of a lung cancer screening trial, unless
hey are independent and review the medical ﬁles blinded and with
redetermined criteria and ﬂowcharts. The aim of this study is to
evelop a CoD review process protocol that will be used in the
utch-Belgian lung cancer CT screening trial (NELSON). The perfor-
ance of the protocol has been tested in a pilot and the outcomes
ill be compared with the ofﬁcial death certiﬁcates.
. Methods
.1. Study design and subjects for the NELSON trial
Details of the design and conduct of the Dutch-Belgian lung can-
er screening trial have been reported elsewhere [15,16].  Brieﬂy,
andomly assigned eligible participants underwent CT screening
t baseline (ﬁrst round), 1 year later (second round), 3 years later
third round) and 5.5-year later (fourth round) or no screening. The
urpose of the trial is to determine whether at 10 years after ran-
omisation, CT screening will have reduced mortality from lung
ancer by at least 25% [16]. The trial was approved by the Dutch
inister of Heath and the ethics board at each participating cen-
re [4].  All participants provided written informed consent for the
valuation of personal data from hospital charts and national regis-
ers. The CoD evaluation process of the NELSON trial was  designed
o ensure a uniform and unbiased determination of the primary
ause of death in participants with lung cancer.
.2. Identiﬁcation of subjects for the CoD review and data
ollection
The cause of death of all participants of the NELSON trial that are
iagnosed with lung cancer (during their lifetime or at autopsy) are
ubject of the ‘review process’ to ensure a valid determination of the
rimary outcome measure of the screening trial. The lung cancer
ases are identiﬁed by linkages with the national cancer registries
f the Netherlands and Belgium and by checking all ofﬁcial death
ertiﬁcates for the diagnosis lung cancer, which are obtained from
tatistics Netherlands and the Flemish Agency for Care and Health.
or all identiﬁed cases, the diagnosis of lung cancer is veriﬁed by a
athology panel [17] or clinical experts for cases without cytology
r histology. This veriﬁcation process of the lung cancer diagnosis
as performed separately from the CoD-veriﬁcation process in the
ELSON-trial and will not be addressed in this manuscript.
After the identiﬁcation of the subjects, all relevant medical infor-
ation will be collected and blinded for the participant’s identity
nd study arm by an individual who is not otherwise involved in the
rial. The medical ﬁles include: information provided by the general
ractitioner, discharge, outpatient visit letters, reports of radiology,
uclear medicine, pathology and microbiology, laboratory results,
nd autopsy reports.
.3. Formation of the clinical expert committeeAll cases will be reviewed and classiﬁed separately by the three
embers of the CEC, who are no employees of the screening
rial. The committee is formed by a pulmonologist–oncologist anddeath is present and lung cancer contributed to
the death of the patient.
pathologist specialised in lung oncology and a clinical epidemiol-
ogist specialised in screening. For a random sample of 10%, cases
with disagreement and all intervention related deaths the commit-
tee will meet. An international committee will be consulted in case
no consensus is reached.
2.4. The cause of death evaluation process protocol
The evaluation process performed by the experts will be guided
by the use a ﬂowchart (Fig. 1a–d in the supplementary data) and
a detailed list of criteria (Appendix 1 in the supplementary data).
The product of the evaluation is the classiﬁcation of the cause of
death of the participant in one of the six categories which deﬁne
graduation of certainty that lung cancer was  the primary cause of
death (Table 1).
2.5. Design and subjects of the CoD pilot
Before the implementation of the protocol we  decided to per-
form a pilot study by ourselves with a limited number of cases
to test its user-friendliness and performance compared with the
ofﬁcial death certiﬁcates. Therefore, we included the ﬁrst ﬁfty
consecutive deceased participants diagnosed with lung cancer. In
contrary to the CEC of externals to be formed for the review of all
lung cancer deaths, a medical doctor (N.H.) and a clinical epidemiol-
ogist (H.J.d.K), internals of the NELSON-trial formed the committee
for the pilot study. The collection and blinding of the medical ﬁles
and the review process itself was  performed as described. After
the completion of the evaluation of the cases by both reviewers
separately, the reviewers met  and discussed the cases with dis-
agreement. Two of the pulmonologist–oncologists of the NELSON
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Table 2
Characteristics of the ﬁfty subjects of the pilot study.
Agea
Mean: 62.6 years
Range: 51–73 years
Gender
Male: 42/50 (84%)
Female: 8/50 (16%)
Base for the diagnosis lung
cancer
Surgical resection of primary tumor:
16/50 (32%)
Histology or cytology of primary
tumor: 15/50 (30%)
Histology or cytology of lymph node
metastasis: 6/50 (12%)
Histology or cytology of distant
metastasis: 8/50 (16%)
Autopsy: 1/50 (2%)
Clinical picture and imaging
techniques: 4/50 (8%)
Disease stage at diagnosisb
IA: 12/50 (24%)
IIA: 2/50 (4%)
IIB: 1/50 (2%)
IIIA: 6/50 (12%)
IIIB: 3/50 (6%)
IV: 26/50 (52%)
a Age at the inclusion in the NELSON trial.
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Table 3
Outcome of the separate review of the cause of death.
Lung cancer death Reviewer 1 Reviewer 2 Level of
agreement
N of 50 (%) N of 50 (%) kappa
Deﬁnitely or probable 41 (82) 42 (84) 0.65
-  Deﬁnitely 33 (66) 41 (82) 0.60
-  Probable 8 (16) 1 (2) 0.19
Possible 1 (2) 0 (0) –
Unlikely 1 (2) 0 (0) –
Deﬁnitely not 3 (6) 7 (14) 0.56
Contributory to other CoD 4 (8) 1 (2) 0.38
CoD: cause of death.
Table 4
The causes of death by the reviewers and the ofﬁcial certiﬁcates.
CoD reviewa Death certiﬁcates
LC death Other CoD Total
N (%) N (%) N (%)
LC death 40 (80) 2 (4) 42 (84)
Other CoD 3 (6) 5 (10) 8 (16)
Total 43 (86) 7 (14) 50 (100)
CoD, cause of death; LC, lung cancer.b TNM staging system for lung cancer 7th edition.
rial (H.J.M.G. and J.-W.J.L.) were consulted in case of persistent
isagreement. After that, the ﬁnal outcome of the pilot study was
ompared with the primary cause of death on the ofﬁcial death
ertiﬁcate.
.6. Analysis
The primary cause of death is deﬁned as ‘the disease that ini-
iated the chain of morbid events directly leading to death’. Lung
ancer mortality, the primary endpoint of the study, is deﬁned as
deﬁnitely” or “probable lung cancer death” (Table 1). “Possible”,
unlikely” and “deﬁnitely no lung cancer death” and “intercurrent
eath with lung cancer as a contributing factor” are considered as
eath due to other causes (Table 1).
The agreement between the two reviewers of the CoD pilot is
ssessed by means of kappa statistics. A kappa of 1 and 0, respec-
ively indicates a perfect agreement and no agreement.
The cause of death, as assigned by the review committee of the
ilot after consensus meeting, is considered as the gold standard.
he sensitivity and speciﬁcity of the ofﬁcial death certiﬁcates were
eﬁned as the proportion of lung cancer deaths assigned by both
ources and as death due to other causes.
Because it is not yet allowed to analyse the data by study arm,
o absolute numbers of lung cancer deaths per arm are disclosed.
herefore, it is not possible to determine if the CoD review process
nhances or attenuates the effect of screening.
. Results
The baseline characteristics, base for the diagnosis of lung can-
er and the disease stage of the ﬁfty subjects that were included in
he pilot are displayed in Table 2. The separate classiﬁcation of the
ause of death by the reviewers is shown in Table 3. In thirty-eight
f the ﬁfty participants (76%) the reviewers reached a concordant
onclusion. The twelve remaining cases with disagreement had;
igniﬁcant comorbidity (3), multiple malignancies (2), death after
n intervention (3) and death indirectly caused by lung cancer (4),
uch as death due to post-obstruction pneumonia or paraneoplas-
ic pulmonary embolism. However, when clustering all “deﬁnitely”
nd “probable” lung cancer deaths into one group and “possible”,a Cause of death after consensus meeting of the reviewers.
“unlikely” and “deﬁnitely not” lung cancer death and “intercurrent
death” into another, the differences were minimal; agreement in
45 cases (90%) resulting in a kappa of 0.65.
The comparison between the results of the CoD review, after
consensus meeting, and the primary cause of death on the ofﬁcial
certiﬁcates is displayed in Table 4. The sensitivity and speci-
ﬁcity of the death certiﬁcates are 95.2% (95% conﬁdence interval:
84.2–98.7%) and 62.5% (95% conﬁdence interval: 30.6–86.3%),
respectively. Disagreement was observed in 10% (5 of 50 individ-
uals) with the following causes of death: adult respiratory distress
syndrome after lobectomy, rupture of an abdominal aneurysm dur-
ing chemotherapy, another malignancy besides lung cancer in two
cases (breast carcinoma and acute myeloid leukaemia) and small
cell lung carcinoma diagnosed after the person’s death by autopsy.
Autopsy was  performed in 3 (6%) of the cases. Five of the 41 (12%)
lung cancer deaths involved euthanasia or palliative sedation. The
place of death was in the hospital in 48%, in a hospice or nursing
home in 10% and at home in 42% of the subjects. In 65% of the cases,
the reviewers indicated the letters of the pulmonologist as the most
valuable source of information.
4. Discussion
In this pilot study, we  have presented the principles of the CoD
review process that will be used in the NELSON trial. The pilot study
of ﬁfty cases has shown an agreement of 90% (kappa 0.65) between
the two reviewers, which demonstrates a reasonable classiﬁcation.
We expect an increase of the level of agreement for the actual
review process, performed by clinical experts, with the number of
cases they evaluate; the so-called ‘learning-effect’.
When comparing to the CoD process, the sensitivity and speci-
ﬁcity of the ofﬁcial death certiﬁcates for lung cancer speciﬁc
mortality were 95.2 and 62.5%, respectively. Despite the lack of a
‘gold standard’ for the cause of death of lung cancer participants,
this still demonstrates, in our opinion, a limited distinctive charac-
ter of the ofﬁcial cause of death certiﬁcation in lung cancer patients
for scientiﬁc purposes.
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Potential limitations of the present study relate to the sam-
le size and the selection of subjects of the pilot study. We  have
aken the ﬁrst ﬁfty consecutive deceased participants that were
iagnosed with lung cancer. This has introduced a selection bias
f individuals with a high lung cancer disease stage at diagnosis
Table 2) compared with the screen-arm of the trial [4].  In the pilot
tudy, most deaths were due to lung cancer. It is plausible that death
ue to other causes than lung cancer plays a bigger part when the
les of all NELSON participants will be reviewed. Hence, the ﬁg-
res demonstrated in the pilot could differ from those of the entire
tudy.
No other lung cancer CT screening trial has published results of
heir methodology of CoD evaluation yet, to our knowledge. In the
hest X-ray screening trials, such as the Mayo Lung Project, Hopkins
nd Sloan-Kettering Lung Trials and the Prostate, Lung, Colorectal
nd Ovarian (PLCO) cancer screening trial, an expert review panel
etermined the CoD [11,18–20].  Lung cancer mortality was  5–6%
verestimated in the intervention arm and 2% underestimated in
he usual-care arm by the death certiﬁcates in these trials [11,18].
n this initial pilot, the misestimate is 10%.
. Conclusion
Our and other studies’ results imply that the outcome of a
ung cancer screening trial cannot reliably be established with-
ut a concordance analysis between vital statistics and a CoD
eview of blinded cases. Moreover, the principles and ﬂowcharts
resented here aim to provide one of the essential tools to
ake data pooling with other CT screening trials in the future
ossible.
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Appendix A. Supplementary data
Supplementary data associated with this article can be
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